Consistent with previous results showing that the administration of anti-PD-1 antibodies can rejuvenate tumor-infiltrating CD8+ T cells, our results indicated that YST-OVH could enhance antitumor efficacy by activating tumor-infiltrating CD8+ T cells. Here, PDCD1 is linked to neoplasm.